Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Monitoring Agency Report for the Quarter ending June 30, 202121-07-2021
21-07-2021
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Monitoring Agency Report for the Quarter ending June 30, 202121-07-2021
Earnings Call for Q1FY22 of Gland Pharma
Conference Call with Gland Pharma Management and Analysts on Q1FY22 Performance and Outlook. Listen to the full earnings transcript.21-07-2021
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Investor Presentation
Earnings Presentation on the Unaudited Financial Results for the Quarter ended June 30, 202121-07-2021
Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release in relation to the Unaudited Financial Results for the Quarter ended June 30, 202121-07-2021
Gland Pharma Ltd - 543245 - Unaudited Financial Results For The Quarter Ended June 30, 2021
The Board of Directors at its meeting held on July 21, 2021 has inter- alia approved the Unaudited Financial Results of the Company for the Quarter ended June 30, 202121-07-2021
Gland Pharma Ltd - 543245 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Reg 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended June 30, 202115-07-2021
Gland Pharma Ltd - 543245 - Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Sampath Kumar PallerlamudiDesignation :- Company Secretary and Compliance Officer09-07-2021
Gland Pharma Ltd - 543245 - Shareholding for the Period Ended June 30, 2021
Gland Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click here06-07-2021
Buy Gland Pharma: target of Rs 4100: Sharekhan
Sharekhan is bullish on Gland Pharma has recommended buy rating on the stock with a target price of Rs 4100 in its research report dated July 05, 2021.06-07-2021